World's Smallest POC Device for Complete Blood Count in 30 Minutes Unveiled

Hilab (Manaus, Brazil), a frontrunner in innovative healthcare solutions, is presenting its groundbreaking technologies at the AACC 2023. Among the highlights are two pivotal launches and a unique point-of-care Hemogram device—the world's only instrument capable of providing a comprehensive blood count using artificial intelligence and other cutting-edge technologies within just 30 minutes.

The company’s pioneering device, the Hilab Lens, marks a substantial leap in digital microscopy. As the smallest point-of-care device that can perform a complete blood count, it operates by medical professionals collecting a fingertip blood sample, much like rapid glucose tests. The procured sample is housed in a capsule and fed into the device, where its information is then transmitted to the company's central laboratory via the Internet of Things. Initially, the sample is validated by artificial intelligence, followed by a specialized hematology healthcare professional. Within half an hour, the test results are dispatched to the patient through an SMS and email, an impressive feat considering traditional methods can take anywhere from 12 to 48 hours.

In addition, Hilab is introducing two more devices at the show—the Hilab Volt and the Hilab Wave. These compact devices will also be remotely connected to the health tech's central laboratory via the Internet. The Hilab Volt, which works on the principles of electrochemistry, reads an electrode that selectively interacts with the sample, generating an insightful analytical electrical signal. It can help evaluate parameters such as calcium, sodium, potassium, iron, and glucose, among others. The Hilab Wave, functioning via spectrophotometry—an optical analysis methodology used for quantitative measurement of light absorption by solutions—facilitates numerous tests, including those for phosphorus, magnesium, cholesterol, Vitamin D, and even for detecting Malaria.

“The complete blood count is so popular because it evaluates the quantity and quality of the main blood components, supporting the assessment and monitoring of acute infectious conditions, anemia evaluation, as well as assessing overall health,” said Bernardo Almeida, an infectious disease physician, and Chief Medical Officer of Hilab. “With the test's ease and speed, medical professionals and patients can benefit from the prompt delivery of results in both routine and emergency cases.”

“Participating in a scientific and international event of this magnitude reinforces Brazil's ability to transform the healthcare sector using technology as an ally,” added Marcus Figueredo, CEO, and co-founder of Hilab. “For Hilab, as a Brazilian company, this is a particularly special and rewarding moment, marking a positive milestone in their history, indicating that they are on the right path by providing quality and innovative services that can address urgent healthcare access issues worldwide.”

Related Links:
Hilab